Literature DB >> 24578132

Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.

Monica Locatelli1, Simona Buelli1, Anna Pezzotta1, Daniela Corna1, Luca Perico1, Susanna Tomasoni1, Daniela Rottoli1, Paola Rizzo1, Debora Conti1, Joshua M Thurman2, Giuseppe Remuzzi3, Carlamaria Zoja1, Marina Morigi4.   

Abstract

Shiga toxin (Stx)-producing Escherichia coli is the offending agent of postdiarrhea-associated hemolytic uremic syndrome (HUS), a disorder of glomerular ischemic damage and widespread microvascular thrombosis. We previously documented that Stx induces glomerular complement activation, generating C3a responsible for microvascular thrombosis in experimental HUS. Here, we show that the presence of C3 deposits on podocytes is associated with podocyte damage and loss in HUS mice generated by the coinjection of Stx2 and LPS. Because podocyte adhesion to the glomerular basement membrane is mediated by integrins, the relevance of integrin-linked kinase (ILK) signals in podocyte dysfunction was evaluated. Podocyte expression of ILK increased after the injection of Stx2/LPS and preceded the upregulation of Snail and downregulation of nephrin and α-actinin-4. Factor B deficiency or pretreatment with an inhibitory antibody to factor B protected mice against Stx2/LPS-induced podocyte dysregulation. Similarly, pretreatment with a C3a receptor antagonist limited podocyte loss and changes in ILK, Snail, and α-actinin-4 expression. In cultured podocytes, treatment with C3a reduced α-actinin-4 expression and promoted ILK-dependent nuclear expression of Snail and cell motility. These results suggest that Stx-induced activation of the alternative pathway of complement and generation of C3a promotes ILK signaling, leading to podocyte dysfunction and loss in Stx-HUS.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Keywords:  acute renal failure; complement; hemolytic uremic syndrome; podocyte

Mesh:

Substances:

Year:  2014        PMID: 24578132      PMCID: PMC4116050          DOI: 10.1681/ASN.2013050450

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  52 in total

Review 1.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression.

Authors:  Moin A Saleem; Michael J O'Hare; Jochen Reiser; Richard J Coward; Carol D Inward; Timothy Farren; Chang Ying Xing; Lan Ni; Peter W Mathieson; Peter Mundel
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

3.  Integrin-linked kinase as a candidate downstream effector in proteinuria.

Authors:  M Kretzler; V P Teixeira; P G Unschuld; C D Cohen; R Wanke; I Edenhofer; P Mundel; D Schlöndorff; H Holthöfer
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

4.  Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Diana Karpman
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

5.  The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys.

Authors:  L Guo; P W Sanders; A Woods; C Wu
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells.

Authors:  A K Hughes; P K Stricklett; D Schmid; D E Kohan
Journal:  Kidney Int       Date:  2000-06       Impact factor: 10.612

7.  Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model.

Authors:  Niels W P Rutjes; Beth A Binnington; Charles R Smith; Mark D Maloney; Clifford A Lingwood
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

8.  Mice deficient in alpha-actinin-4 have severe glomerular disease.

Authors:  Claudine H Kos; Tu Cam Le; Sumita Sinha; Joel M Henderson; Sung Han Kim; Hikaru Sugimoto; Raghu Kalluri; Robert E Gerszten; Martin R Pollak
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

9.  The intermediate filament nestin is highly expressed in normal human podocytes and podocytes in glomerular disease.

Authors:  Julie Perry; Michael Ho; Sandra Viero; Keqin Zheng; Robert Jacobs; Paul S Thorner
Journal:  Pediatr Dev Pathol       Date:  2007 Sep-Oct

Review 10.  Cell biology of the glomerular podocyte.

Authors:  Hermann Pavenstädt; Wilhelm Kriz; Matthias Kretzler
Journal:  Physiol Rev       Date:  2003-01       Impact factor: 37.312

View more
  26 in total

1.  Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.

Authors:  Federica Casiraghi; Marta Todeschini; Nadia Azzollini; Paolo Cravedi; Paola Cassis; Samantha Solini; Sonia Fiori; Cinzia Rota; Aida Karachi; Camillo Carrara; Marina Noris; Norberto Perico; Giuseppe Remuzzi
Journal:  Transplantation       Date:  2019-06       Impact factor: 4.939

2.  C3a receptor blockade protects podocytes from injury in diabetic nephropathy.

Authors:  Marina Morigi; Luca Perico; Daniela Corna; Monica Locatelli; Paola Cassis; Claudia Elisa Carminati; Silvia Bolognini; Carlamaria Zoja; Giuseppe Remuzzi; Ariela Benigni; Simona Buelli
Journal:  JCI Insight       Date:  2020-03-12

3.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

4.  CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).

Authors:  Caroline Caillaud; Ariane Zaloszyc; Christoph Licht; Valérie Pichault; Véronique Frémeaux-Bacchi; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 5.  Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease.

Authors:  Lili Zhou; Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2015-06-09       Impact factor: 28.314

Review 6.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

Review 7.  Podocyte-actin dynamics in health and disease.

Authors:  Luca Perico; Sara Conti; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

Review 8.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

9.  The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.

Authors:  Stefan Michelfelder; Friedericke Fischer; Astrid Wäldin; Kim V Hörle; Martin Pohl; Juliana Parsons; Ralf Reski; Eva L Decker; Peter F Zipfel; Christine Skerka; Karsten Häffner
Journal:  J Am Soc Nephrol       Date:  2018-01-15       Impact factor: 10.121

10.  Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.

Authors:  Masayuki Ozaki; Yulin Kang; Ying Siow Tan; Vasile I Pavlov; Bohan Liu; Daniel C Boyle; Rafail I Kushak; Mikkel-Ole Skjoedt; Eric F Grabowski; Yasuhiko Taira; Gregory L Stahl
Journal:  Kidney Int       Date:  2016-07-01       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.